Navigation Links
A hijacking of healthy cellular circuits
Date:4/8/2013

April 8, 2013, New York, NY and San Diego Calif. Proteins that control cell growth are often mutated in cancer, and their aberrant signaling drives the wild proliferation of cells that gives rise to tumors. One such protein, the epidermal growth factor receptor (EGFR), fuels a wide variety of cancersincluding a highly malignant brain cancer known as glioblastoma. Yet drugs devised to block its signaling tend to work only for a short while, until the cancer cells adapt to evade the therapy. So far, much of the research examining such drug resistance has focused on how mutations of other proteins in cancer cells allow them to resist drugs.

But not all drug-resistant tumors harbor those additional mutations, suggesting that they have evolved alternative resistance mechanisms. In the current issue of Cancer Discovery, a team led by Paul Mischel at the Ludwig Institute for Cancer Research and Steven Bensinger at the University of California, Los Angeles, identifies a unique mechanism by which glioblastoma cells develop resistance to drugs that target EGFR signaling. The cells accomplish this feat not through mutation, but by hijacking the signaling of a perfectly normal cell surface receptor named platelet-derived growth factor receptor-β (PDGFRβ). Targeting both receptors at once, the researchers report, prevents resistance and suppresses glioblastoma tumors in laboratory models.

"Our findings highlight the remarkable adaptability of cancer cells and how they harness multiple mechanisms to maintain the growth signals critical to their survival. These results could have implications for our understanding of a wide variety of cancers," says Mischel, MD, member of the Ludwig Institute at the University of California San Diego.

Mischel, Bensinger and their colleagues began their study by exploring how blocking EGFR alters signaling in glioblastoma cells. To do so, they transplanted into mice glioblastoma tumors that are naturally fueled by a permanently activated mutant of EGFR. They then treated the mice with a drug named erlotinib, which inhibits EGFR.

What they saw was that one receptor in particularPDGFRβwas highly expressed and active in all treated tumor cells, but virtually absent in tumors that were spared treatment. The researchers detected the same pattern in cultures of cells derived from a variety of glioblastoma tumors. This suggested that cancer cells in which EGFR signaling is blocked respond by expressing PDGFRβ to compensate for the loss of that critical signal.

To determine whether the phenomenon occurred in patients as well, the team examined tumor samples collected in a clinical trial of another EGFR-targeting drug named lapatinib. "Across tumors," says Mischel, "we saw a reciprocal relationship between the activation of PDGFRβ and the mutant form of the EGFR. This established that what we were seeing in lab experiments was happening in people actually undergoing treatment with EGFR targeting drugs."

Using pharmacologic and genetic techniques to tease apart the signaling pathways responsible for this effect, the researchers found that two distinct biochemical circuits switched on by EGFR suppressed the expression of the PDGFRβ gene. One is mediated by a protein named mTORC1, and another by a protein named MEK. "When one blocks EGFR signaling with a drug," explains Mischel, "that repression is lifted. But, more importantly, these tumors do not need PDGFRβ signaling to survive until you block EGFR." At that point, the tumors become highly dependent on PDGFRβ.

"It's almost like a game of whack-a-mole," says Mischel. "You use a drug to suppress a choice target, and something else pops up to take its place and keep the cells alivein this case a growth factor receptor that is perfectly normal in physiological terms." Notably, such resistance mechanisms, unlike genetic mutation, are very difficult to anticipate.

When they are, however, they can illuminate novel therapeutic strategies. Mischel and Bensinger's team found, for example, that both glioblastoma cell cultures derived from patients and tumors transplanted into mice were potently suppressed when both receptors were blocked at once. "This suggests that if you target both receptors," says Mischel, "you might be able to prevent drug resistance."

Though the study led by Mischel and Bensinger focuses on glioblastoma, its findings are relevant to many other cancersand not just because aberrant EGFR signaling drives the growth of many types of tumors.

The next step, Mischel says, is to test in clinical trials how targeting both receptors affects the treatment of glioblastoma. He and his colleagues also hope to work with other Ludwig researchers to explore small molecule inhibitors of PDGFRβ and to examine whether similar drug resistance mechanisms are found in other cancers as well.


'/>"/>

Contact: Rachel Steinhardt
rsteinhardt@licr.org
212-450-1582
Ludwig Institute for Cancer Research
Source:Eurekalert

Related biology news :

1. Horticultural hijacking
2. To drive infections, a hijacking virus mimics a cells signaling system
3. Unhealthy eating can make a bad mood worse
4. Stronger support needed for healthy beverage practices in child care
5. Neuronal activity induces tau release from healthy neurons
6. Building healthy bones takes guts
7. Healthy seeds -- treated environmentally friendly
8. Poor mental health leads to unhealthy behaviors among low-income adults
9. Foods identified as whole grain not always healthy
10. UC Davis study deflates notion that pear-shaped bodies more healthy than apples
11. R U eating healthy 2day?
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... 2016  Neurotechnology, a provider of high-precision biometric ... Biometric Identification System (ABIS) , a complete system ... ABIS can process multiple complex biometric transactions with ... fingerprint, face or iris biometrics. It leverages the ... MegaMatcher Accelerator , which have been used ...
(Date:4/26/2016)... Research and Markets has announced ... 2016-2020"  report to their offering.  , ,     (Logo: ... analysts forecast the global multimodal biometrics market to ... period 2016-2020.  Multimodal biometrics is being ... the healthcare, BFSI, transportation, automotive, and government for ...
(Date:4/14/2016)... AVIV, Israel , April 14, 2016 ... Behavioral Authentication and Malware Detection, today announced the appointment ... already assumed the new role. Goldwerger,s leadership ... BioCatch, on the heels of the deployment of its ... addition, BioCatch,s behavioral biometric technology, which discerns unique cognitive ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... ... 23, 2016 , ... ClinCapture, the only free validated electronic ... showcase its product’s latest features from June 26 to June 30, 2016 for ... Disrupting Clinical Trials in The Cloud during the conference. DIA (Drug Information ...
(Date:6/23/2016)... ... June 23, 2016 , ... Velocity Products, a division ... tuned and optimized exclusively for Okuma CNC machining centers at The International Manufacturing ... collaboration among several companies with expertise in toolholding, cutting tools, machining dynamics and ...
(Date:6/23/2016)... , June 23, 2016 ... research report to its pharmaceuticals section with historic ... details and much more. Complete report ... 151 pages, profiling 15 companies and supported with ... http://www.reportsnreports.com/reports/601420-global-cell-culture-media-industry-2016-market-research-report.html . The Global ...
(Date:6/22/2016)... , June 22, 2016 Research and ... Global Markets" report to their offering. ... billion in 2014 from $29.3 billion in 2013. The market is ... of 13.8% from 2015 to 2020, increasing from $50.6 billion in ... projected product forecasts during the forecast period (2015 to 2020) are ...
Breaking Biology Technology: